Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)

NCT06238622 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06238622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 26, 2024
Completion date
May 7, 2027
Enrollment
1,666 (actual)
Sites
374

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, progressive pulmonary fibrosis